Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
01 Febbraio 2024 - 12:30PM
Verve Therapeutics, a clinical-stage biotechnology company
pioneering a new approach to the care of cardiovascular disease
with single-course gene editing medicines, today announced that
Sekar Kathiresan, M.D., co-founder and chief executive officer,
will participate in a fireside chat at the Guggenheim Healthcare
Talks 6th Annual Biotechnology Conference on Thursday, February 8,
2024 at 11:30 a.m. ET in New York.
A live webcast will be available in the investor section of the
company's website at www.vervetx.com. The webcast will be archived
for 30 days following the presentation.
About Verve Therapeutics Verve
Therapeutics, Inc. is a clinical-stage genetic medicines company
pioneering a new approach to the care of cardiovascular disease,
potentially transforming treatment from chronic management to
single-course gene editing medicines. The company’s initial three
programs – VERVE-101, VERVE-102, and VERVE-201 – target genes that
have been extensively validated as pharmacologic targets for
lowering low-density lipoprotein cholesterol (“LDL-C”), a root
cause of cardiovascular disease, in order to durably reduce blood
LDL-C levels.
Investor ContactJen RobinsonVerve Therapeutics,
Inc.jrobinson@vervetx.com
Media ContactAshlea
Kosikowski1ABashlea@1abmedia.com
Grafico Azioni Verve Therapeutics (NASDAQ:VERV)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Verve Therapeutics (NASDAQ:VERV)
Storico
Da Giu 2023 a Giu 2024